Multimodal MRI was used to longitudinally monitor the effects of a novel combination therapy of radiosurgery and programmed death-ligand 1 (PD-1) checkpoint inhibitor in a mouse model of GBM. We found that combination therapy of radiosurgery and immune checkpoint inhibition was more effective in reducing tumor volume and yielded better survival compared to non-treated, radiation-alone or immunotherapy-alone group. At 30-day post-treatment onset, tumor-ROI T2, apparent-diffusion coefficient, fractional anisotropy, and kurtosis of the combination treatment group were significantly different from those of the non-treated group (p<0.05). Immunohistochemical results further shed light on possible mechanisms of action.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords